bearish
Pre-IPO Genecast Group - NGS Still Has Long Way to Go; Valuation Performance Is Worrying
333 Views16 Nov 2023 08:55
Genecast’s business faces different challenges as NGS hasn't developed as rigid demand. It's difficult for Genecast to make profits in the short term. Valuation performance after IPO is also a concern
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
x